

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

July 9, 2021

Beth Hecht, Esq. General Counsel Xeris Biopharma Holdings, Inc. 180 N. LaSalle Street, Suite 1600 Chicago, IL 60601

> Re: Xeris Biopharma Holdings, Inc. Registration Statement on Form S-4 Filed July 2, 2021 File No. 333-257642

Dear Ms. Hecht:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Laura Crotty at 202-551-7614 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Joseph C. Theis, Jr., Esq.